Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New HPV vaccine aims to shield against more cancer types than ever before

NCT ID NCT06688058

First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 26 times

Summary

This early-stage study tests a new vaccine called V540D in 72 healthy adults. The vaccine is designed to protect against the same nine HPV types as the current GARDASIL®9 vaccine, plus additional HPV types that can cause cancer. The main goal is to check if the vaccine is safe and well-tolerated, while also measuring the immune response compared to the standard vaccine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Alliance for Multispecialty Research, LLC ( Site 0003)

    Kansas City, Missouri, 64114, United States

  • Alliance for Multispecialty Research, LLC ( Site 0004)

    Knoxville, Tennessee, 37920, United States

  • Research Centers of America ( Hollywood ) ( Site 0001)

    Hollywood, Florida, 33024, United States

  • Velocity Clinical Research, Savannah ( Site 0005)

    Savannah, Georgia, 31406, United States

Conditions

Explore the condition pages connected to this study.